About Iconovo
Iconovo is a company based in Lund (Sweden) founded in 2013. Iconovo has raised $3.56 million across 4 funding rounds from investors including Gates Foundation and Vinnova. Iconovo operates in a competitive market with competitors including MannKind Corp, Impel NeuroPharma, Alexza, OptiNose and Qnovia, among others.
- Headquarter Lund, Sweden
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
$265.64 K (USD)-58.55as on Dec 31, 2024
-
Net Profit
-$3.73 M (USD)10.36as on Dec 31, 2024
-
EBITDA
-$2.76 M (USD)30.28as on Dec 31, 2024
-
Total Equity Funding
$3.56 M (USD)
in 4 rounds
-
Latest Funding Round
$883.8 K (USD), Grant
Jul 26, 2022
-
Investors
Gates Foundation
& 1 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Iconovo
Iconovo has successfully raised a total of $3.56M across 4 strategic funding rounds. The most recent funding activity was a Grant round of $883.8 thousand completed in July 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Grant — $883,800
- First Round First Round
- Investors Count 2
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2022 | Amount | Grant - Iconovo | Valuation |
investors |
|
| Jun, 2017 | Amount | Series A - Iconovo | Valuation |
investors |
|
| Oct, 2014 | Amount | Seed - Iconovo | Valuation |
investors |
|
Investors in Iconovo
Iconovo has secured backing from 2 investors, including institutional and venture fund investors. Prominent investors backing the company include Gates Foundation and Vinnova.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital funding is provided to Swedish companies across sectors.
|
Founded Year | Domain | Location | |
|
Charitable foundation investments on poverty reduction and healthcare
|
Founded Year | Domain | Location |
Investments & Acquisitions by Iconovo
Financial Statements - Iconovo
Iconovo Comparisons
Competitors of Iconovo
Iconovo operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as MannKind Corp, Impel NeuroPharma, Alexza, OptiNose and Qnovia, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of small-molecule drugs
|
|
| domain | founded_year | HQ Location |
Intranasal delivery technology for CNS diseases is developed.
|
|
| domain | founded_year | HQ Location |
Developer of products for the treatment of acute and intermittent conditions
|
|
| domain | founded_year | HQ Location |
Developer of smart devices for nasal drug delivery
|
|
| domain | founded_year | HQ Location |
Inhaled drug delivery devices are developed for pharmaceuticals.
|
|
| domain | founded_year | HQ Location |
Therapeutics for cardiopulmonary diseases are developed using inhaled therapies.
|
Frequently Asked Questions about Iconovo
Iconovo was founded in 2013.
Iconovo is headquartered in Lund, Sweden.
Iconovo is a funded company, having raised a total of $3.56M across 4 funding rounds to date. The company's 1st funding round was a Seed of $1M, raised on Nov 23, 2013.
Annual revenue of Iconovo is $265.64K as on Dec 31, 2024.
Iconovo was founded in 2013 as a medical device company based in Lund, Sweden. Inhalation devices are developed, focusing on dry powder inhalers such as ICOres for reservoir-based delivery, ICOcap for capsule-based use, ICOone as a unit-dose disposable option, and ICOpre with pre-metered doses sealed during manufacturing. Operations center on innovative drug delivery solutions within the healthcare sector.
Iconovo's top competitors include MannKind Corp, OptiNose and Impel NeuroPharma.
Iconovo has 2 investors. Key investors include Gates Foundation, and Vinnova.